Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 arti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2018-03-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2018-0010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572085677850624 |
|---|---|
| author | Wu Jian Yin Fang Zhou Xinmin |
| author_facet | Wu Jian Yin Fang Zhou Xinmin |
| author_sort | Wu Jian |
| collection | DOAJ |
| description | The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment. |
| format | Article |
| id | doaj-art-9c603c9abf6f41158497d8cc88aa2d71 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2018-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-9c603c9abf6f41158497d8cc88aa2d712025-02-02T12:01:38ZengSciendoActa Pharmaceutica1846-95582018-03-01681193010.2478/acph-2018-0010acph-2018-0010Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysisWu Jian0Yin Fang1Zhou Xinmin2Digestion Internal Medicine Department, Xijing Hospital The First Affiliated Hospital of the Fourth Military Medical University Xi’an Shaanxi 710000, ChinaDigestion Internal Medicine Department, Xijing Hospital The First Affiliated Hospital of the Fourth Military Medical University Xi’an Shaanxi 710000, ChinaDigestion Internal Medicine Department, Xijing Hospital The First Affiliated Hospital of the Fourth Military Medical University Xi’an Shaanxi 710000, ChinaThe purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment.https://doi.org/10.2478/acph-2018-0010liver failurehepatitis b virusnucleoside analoguetenofovirnetwork meta-analysis |
| spellingShingle | Wu Jian Yin Fang Zhou Xinmin Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis Acta Pharmaceutica liver failure hepatitis b virus nucleoside analogue tenofovir network meta-analysis |
| title | Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis |
| title_full | Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis |
| title_fullStr | Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis |
| title_full_unstemmed | Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis |
| title_short | Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis |
| title_sort | efficacy of nucleoside analogues for hepatitis b virus related liver failure a network meta analysis |
| topic | liver failure hepatitis b virus nucleoside analogue tenofovir network meta-analysis |
| url | https://doi.org/10.2478/acph-2018-0010 |
| work_keys_str_mv | AT wujian efficacyofnucleosideanaloguesforhepatitisbvirusrelatedliverfailureanetworkmetaanalysis AT yinfang efficacyofnucleosideanaloguesforhepatitisbvirusrelatedliverfailureanetworkmetaanalysis AT zhouxinmin efficacyofnucleosideanaloguesforhepatitisbvirusrelatedliverfailureanetworkmetaanalysis |